SCHEMBL6350290

SCHEMBL6350290

c1cc(-c2cncc(N3CCNCC3)c2)co1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 7/20 0.51
CHRNA4 P43681 7/20 0.51
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP2D6 P10635 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
CHRNA1 P02708 1/20 0.47
CHRNA7 P36544 1/20 0.47
TGFBR1 P36897 2/20 0.46
ACVR1B P36896 1/20 0.44
ACVR1 Q04771 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6354045 0.83 CYP1A2 (0.53) CYP1A2CYP3A4USP2ALDH1A1CYP2D6
SCHEMBL3442203 0.79 HTR7 (0.67) CYP1A2CYP3A4USP2ALDH1A1CYP2D6
SCHEMBL6351651 0.79 ADRB2 (0.61) CHRNB2CHRNA4CHRNA1CHRNA7TGFBR1
SCHEMBL3453352 0.79 HTR1A (0.66) CHRNB2CHRNA4CHRNA1CHRNA7TGFBR1
Hydrochloric Acid SCHEMBL3268024 0.78 HTR1A (0.64) CHRNB2CHRNA4CHRNA1CHRNA7TGFBR1
SCHEMBL4915501 0.77 HTR1A (0.47) CYP1A2CYP3A4USP2ALDH1A1CYP2D6
SCHEMBL22236832 0.77 CHRNB2 (0.67) CHRNB2CHRNA4CHRNA1CHRNA7TGFBR1
SCHEMBL22236804 0.77 TGFBR1 (0.58) CHRNB2CHRNA4CHRNA1CHRNA7TGFBR1
SCHEMBL6348853 0.77 CHRNB2 (0.61) CHRNB2CHRNA4CYP1A2CYP3A4ALDH1A1
SCHEMBL18790712 0.77 HTR1A (0.64) CHRNB2CHRNA4CHRNA1CHRNA7TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897219-B2 Heteroaryl diazacycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2005-05-24 US disclosed
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US disclosed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US disclosed
CN-1131211-C Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2003-12-17 CN disclosed
CN-1277604-A Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2000-12-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; OGFR, CBR3, OGFRL1 CHRNB2 700/4885CHRNA4 1019/4885CYP1A2 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.